drugset / Trial / NCT01319487

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

NCT01319487 ↗

Phase 2 Completed 267 enrolled Fovea Pharmaceuticals SA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment.

Timeline

Start
2011-05
Primary completion
2012-03
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SAFOTIBANT Small molecule — Topical